Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vektor Pharma Tf GmbH currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, GOTFREDSON, GAREN, who is the busiest examiner with 1 pending action. The prosecution is limited to 1 distinct art unit. This 1 to 1 relationship between the pending action, the examiner, and the art unit reflects a highly focused and centralized prosecution profile. With only 1 pending office action, the company's entire active presence at the patent office is concentrated in this one matter.
Practitioners must tailor their strategy specifically to the preferences of GOTFREDSON, GAREN, as there are no other examiners involved in the portfolio to provide a broader perspective. The concentration in 1 distinct art unit within the Biotechnology & Pharmaceuticals field suggests that the technology is specialized. Because there is only 1 pending action, every procedural step is critical to the company's intellectual property goals. The prosecution team should focus on the specific guidelines of the 1 assigned art unit to ensure that this single matter proceeds efficiently. The outcome of this 1 pending office action will be the sole indicator of the company's current success in patent acquisition.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOTFREDSON, GAREN | 1 | 40.0% | +28.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19307513 | Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases | GOTFREDSON, GAREN | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19307513 | Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases | GOTFREDSON, GAREN | 1619 | §103DP | Non-Final OA | 5d overdue | Pending | Aug 22, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial